December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Imetelstat, a telomerase inhibitor, shows dose-dependent improvements in OS and trends in correlation with other clinical benefits in patients with JAK inhibitor–refractory, high-risk myelofibrosis.